Published in Hepatitis Weekly, July 10th, 2006
"In this study, we evaluated whether hepatic steatosis affects the viral response to IFN and ribavirin combination therapy in Japanese patients with CHC," wrote R. Yaginuma and colleagues, Juntendo University.
They explained, "Eighty CHC patients treated with IFN alpha-2b and ribavirin for 24 weeks were evaluated retrospectively. Liver biopsy specimens were assessed histopathologically, and grade of steatosis was scored as follows:...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.